Juvenescence CEO Dr Greg Bailey Set to Speak at Web Summit 2022

Biotech Leader to Provide Longevity Insights at Annual Conference 

Ramsey, Isle of Man – November 1, 2022 – Juvenescence Limited (“Juvenescence”), a life sciences company developing therapies and consumer products to modify and support heathy aging and increase healthspan, is pleased to announce that its Co-Founder and CEO, Dr Gregory Bailey has been selected to speak at Web Summit 2022. Web Summit 2022 will bring together 70,000+ people, and the companies redefining the tech industry. The summit will be held in Lisbon, Portugal and runs from November 1-4. 

Dr Bailey will provide opening remarks and will host the afternoon session at WebSummit’s HealthConf track where industry giants, disruptive startups, investors & innovators gather to redefine healthcare. 

Friday, 4 November 13:20 - 13:35 
Dr. Bailey is driven by the opportunity to truly modify the ageing process. The goal? To use his track record and drug development expertise, and that of his partners, to find compelling products to fulfill the promise of Juvenescence. 

Juvenescence portfolio company, Relation Therapeutics, will also speak at the conference. Dr David Roblin will discuss advancements in science and technology that have led to extraordinary insights into human health and disease and how this information translates into modern medicine. 

Thursday, 3 November 16:30 - 16:42 
Join Relation CEO, Dr. David Roblin, as he shares how we can harness drug discovery to build a new kind of biotech. The patient is waiting. 

 Please email juvenescenceir@juvlabs.com if you are interested in connecting with Dr Bailey and Juvenescence at the event. 


About Juvenescence Ltd. 

Juvenescence Ltd. is a life sciences company developing therapies to modify aging and increase healthspan. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers and investors with a significant history of success in the pharmaceutical and consumer health sectors. The company is committed to inspiring and equipping the world to not just reimagine what it means to get older but to help people reimagine their lifetime.                                                            
Juvenescence has a broad portfolio of products in development and is driving innovation amongst two divisions: JuvTherapeutics— Focused on traditional prescription medicines to modify aging and prevent diseases, and JuvLife— Consumer products that manage aging and help increase health span. For more information: https://www.juvlabs.com 


Contact Information 

Juvenescence:            juvenescenceir@juvlabs.com